BioCryst Pharmaceuticals (CH:BO1)
NASDAQ:BO1
BO1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
ORLADEYO Commercial MomentumSustained prescription growth, steady monthly prescriber additions (~60/month) and ~60% one‑year retention create a predictable recurring revenue base. Maintaining 2026 ORLADEYO guidance indicates durable demand and cash visibility, supporting reinvestment and commercialization scale.
Marked Improvement In Cash Generation & LiquidityMaterial positive operating and free cash flows convert revenue into internal funding, reducing near‑term external financing needs. Improved liquidity and cash coverage of accounting losses bolster runway to fund Phase‑3/BLA activities and commercialization, despite historical volatility.
Pipeline Progress And European License For NavenibartCompleting pivotal ALPHA‑ORBIT enrollment and a European license de‑risks regional commercialization costs while preserving milestone and royalty upside. This expands addressable markets, accelerates potential revenue streams, and lets BioCryst focus U.S. commercial resources on ORLADEYO and U.S. filings.
Bears Say
Persistent Negative Shareholders' EquityNegative shareholders' equity constrains financial flexibility and increases refinancing risk over time. It weakens the company's capacity to absorb setbacks, complicates access to favorable financing, and makes standard return metrics less informative for assessing long‑term capital efficiency.
Dilution And Increased Leverage From Astria DealThe Astria acquisition materially diluted existing equity and added a large non‑cash GAAP charge, while the new credit facility raises leverage. These structural capital changes pressure future EPS, increase fixed obligations, and constrain strategic flexibility during integration and pipeline execution.
Intensifying Competitive Pressure In HAEEmerging injectable competitors and new entrants can erode ORLADEYO pricing, retention and share over time. Structural competition in a rare disease market pressures durable margins and requires sustained commercial investment to defend prescriber relationships and patient adherence.
BioCryst News
BO1 FAQ
What was BioCryst Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is BioCryst Pharmaceuticals’s market cap?
Currently, no data Available
When is BioCryst Pharmaceuticals’s upcoming earnings report date?
BioCryst Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 32 days.
How were BioCryst Pharmaceuticals’s earnings last quarter?
BioCryst Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$2.328 earnings per share for the quarter, missing the consensus estimate of $0.034 by -$2.362.
Is BioCryst Pharmaceuticals overvalued?
According to Wall Street analysts BioCryst Pharmaceuticals’s price is currently Undervalued.
Does BioCryst Pharmaceuticals pay dividends?
BioCryst Pharmaceuticals does not currently pay dividends.
What is BioCryst Pharmaceuticals’s EPS estimate?
BioCryst Pharmaceuticals’s EPS estimate is 0.12.
How many shares outstanding does BioCryst Pharmaceuticals have?
Currently, no data Available
What happened to BioCryst Pharmaceuticals’s price movement after its last earnings report?
BioCryst Pharmaceuticals reported an EPS of -$2.328 in its last earnings report, missing expectations of $0.034. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of BioCryst Pharmaceuticals?
Currently, no hedge funds are holding shares in CH:BO1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioCryst Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.89 (― Downside)
$18.89 (― Downside)
Insider Transactions
Sold Shares
Worth CHF489.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.89%
12-Months-Change
Fundamentals
Return on Equity
123.57%
Trailing 12-Months
Asset Growth
-3.12%
Trailing 12-Months
Company Description
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
BO1 Company Deck
BO1 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial execution and progressing late-stage and early-stage pipeline programs, with double-digit revenue and operating profit growth on a non-GAAP basis, meaningful licensing and financing activity that bolsters liquidity, and positive clinical momentum for navenibart and BCX17725. Key negatives include a manufacturing delay for the pediatric pellet fulfillment (timing uncertain), a large GAAP in-process R&D charge of $698M from the Astria acquisition, increased R&D spend and financing/dilution to fund the deal, and ongoing competitive entrants in the HAE market. Management maintained 2026 guidance and emphasized confidence in ORLADEYO demand and pipeline execution.View all CH:BO1 earnings summariesBO1 Stock 12 Month Forecast
Average Price Target
$18.89
Options Prices
Currently, No data available
---